Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Micrus Endovascular Announces Positive DeltaPaq Microcoil Study Results
Micrus Endovascular Corporation (NASDAQ:MEND) announced that study results presented recently at the 10th Congress of the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) demonstrated that the DeltaPaq™ microcoil"s proprietary design appears to improve the uniformity of coil distribution within a cerebral aneurysm and the degree of microcoil packing in the aneurysm dome and neck, which may reduce the risk of aneurysm recurrence. Bernard R. Bendok, M.D., Assistant Professor of Neurological Surgery and Radiology, Department of Neurological Surgery of Northwestern University Feinberg School of Medicine, and Matthew Gounis, Ph.D., Director of the New England Center for Stroke Research at the University of Massachusetts, served as principal investigators for the Micrus-sponsored in vitro study.

Pandemic Could Overwhelm Critical Care Beds In England, Especially Children's Units
Experts in intensive care and anaesthesia have predicted that the current swine flu pandemic could overwhelm critical care beds and ventilators in England, with hospitals on the South East Coast, and in the South West, East of England and East Midlands, being worst hit.
News of the day
Health And Safety Executive Warns Of Dangers In Failing To Maintain Plant Equipment After Driver's Death, UK
The Health and Safety Executive has warned of the danger of not maintaining plant equipment after the death of a telescopic forklift truck driver, who was crushed between the descending arm and side of his vehicle.
Endocrinology

Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment

Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times reports. The FDA approved the first once-daily HIV treatment Atripla in 2006 (7/16). The new antiretroviral drug would contain Tibotec"s experimental non-nucleoside reverse transcriptase inhibitor, known as TMC278, and Gilead"s combination pill, Truvada. Kevin Young, head of commercial operations at Gilead "said the new combination pill, along with Gilead"s experimental "quad" pill, will be used for newly-diagnosed patients, with physicians reluctant to change therapy for patients who are responding well to Atripla," Reuters reports. Young said the drug is expected to reach the market in 2011 (Beasley, 7/16). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009